AGY — Allergy Therapeutics Share News
0.000.00%
Last trade - 00:00- £345.57m
- £368.41m
- £55.20m
REG - Allergy Therapeutics - Commencement of Phase III Paediatric Trial
AnnouncementREG - Allergy Therapeutics - Update on funding
AnnouncementREG - Allergy Therapeutics - Update on funding and preliminary results
AnnouncementREG - Allergy Therapeutics - Progression of patient cohorts in PROTECT Trial
AnnouncementREG - Allergy Therapeutics - Update on funding
AnnouncementREG - Allergy Therapeutics - Trading update for the year ended 30 June 2024
AnnouncementREG - Allergy Therapeutics - Appointment of Nominated Adviser and Sole Broker
AnnouncementREG - Allergy Therapeutics - Launch of new Company Long Term Incentive Plan
AnnouncementREG - Allergy Therapeutics - Appointment of Non-Executive Director
AnnouncementREG - Allergy Therapeutics - Progression of patient cohorts in PROTECT Trial
AnnouncementREG - Allergy Therapeutics - Successful meetings with Paul Ehrlich Institut
AnnouncementRCS - Allergy Therapeutics - Allergy Therapeutics presents findings at EAACI
AnnouncementREG - Allergy Therapeutics - Further detail from G306 Phase III field trial
AnnouncementREG - Allergy Therapeutics - Director Resignation
AnnouncementREG - Allergy Therapeutics - Interim Results for six months ended 31 Dec 2023
AnnouncementREG - Allergy Therapeutics - Update on funding
AnnouncementREG - Allergy Therapeutics - VLP Peanut PROTECT Trial Update
AnnouncementRCS - Allergy Therapeutics - VLP Peanut PROTECT Trial Update
AnnouncementREG - Allergy Therapeutics - Appointment of Shaun Furlong to Board of Directors
Announcement